Robinson H, Moerke M, Banks M, Negus S
Exp Clin Psychopharmacol. 2023; 31(6):1080-1091.
PMID: 37184942
PMC: 10788965.
DOI: 10.1037/pha0000655.
Wise R, Jordan C
J Biomed Sci. 2021; 28(1):83.
PMID: 34852810
PMC: 8638539.
DOI: 10.1186/s12929-021-00779-7.
Altshuler R, Carpenter C, Franke T, Gnegy M, Jutkiewicz E
Psychopharmacology (Berl). 2019; 236(11):3231-3242.
PMID: 31134292
PMC: 6832797.
DOI: 10.1007/s00213-019-05278-0.
Keeley R, Bye C, Trow J, McDonald R
F1000Res. 2018; 7:342.
PMID: 29770212
PMC: 5920568.
DOI: 10.12688/f1000research.14029.2.
Morozova E, Yoo Y, Behrouzvaziri A, Zaretskaia M, Rusyniak D, Zaretsky D
Physiol Rep. 2016; 4(17).
PMID: 27604402
PMC: 5027360.
DOI: 10.14814/phy2.12955.
Amphetamine elevates nucleus accumbens dopamine via an action potential-dependent mechanism that is modulated by endocannabinoids.
Covey D, Bunner K, Schuweiler D, Cheer J, Garris P
Eur J Neurosci. 2016; 43(12):1661-73.
PMID: 27038339
PMC: 5819353.
DOI: 10.1111/ejn.13248.
Engineering Human Cooperation : Does Involuntary Neural Activation Increase Public Goods Contributions?.
Burnham T, Hare B
Hum Nat. 2015; 18(2):88-108.
PMID: 26181843
DOI: 10.1007/s12110-007-9012-2.
Persistent palatable food preference in rats with a history of limited and extended access to methamphetamine self-administration.
Caprioli D, Zeric T, Thorndike E, Venniro M
Addict Biol. 2015; 20(5):913-26.
PMID: 25582886
PMC: 4499505.
DOI: 10.1111/adb.12220.
The development and maintenance of drug addiction.
Wise R, Koob G
Neuropsychopharmacology. 2013; 39(2):254-62.
PMID: 24121188
PMC: 3870778.
DOI: 10.1038/npp.2013.261.
Dopaminergic therapy removal differentially effects learning in schizophrenia and Parkinson's disease.
Weickert T, Mattay V, Das S, Bigelow L, Apud J, Egan M
Schizophr Res. 2013; 149(1-3):162-6.
PMID: 23830543
PMC: 5124763.
DOI: 10.1016/j.schres.2013.06.028.
Opiate versus psychostimulant addiction: the differences do matter.
Badiani A, Belin D, Epstein D, Calu D, Shaham Y
Nat Rev Neurosci. 2011; 12(11):685-700.
PMID: 21971065
PMC: 3721140.
DOI: 10.1038/nrn3104.
Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.
Comer S, Bickel W, Yi R, de Wit H, Higgins S, Wenger G
Behav Pharmacol. 2010; 21(4):251-77.
PMID: 20664330
PMC: 2913311.
DOI: 10.1097/FBP.0b013e32833bb9f8.
Amphetamines.
Bull World Health Organ. 2010; 43 Suppl:66-76.
PMID: 20604377
PMC: 2427604.
Roles for nigrostriatal--not just mesocorticolimbic--dopamine in reward and addiction.
Wise R
Trends Neurosci. 2009; 32(10):517-24.
PMID: 19758714
PMC: 2755633.
DOI: 10.1016/j.tins.2009.06.004.
Dopamine and reward: the anhedonia hypothesis 30 years on.
Wise R
Neurotox Res. 2008; 14(2-3):169-83.
PMID: 19073424
PMC: 3155128.
DOI: 10.1007/BF03033808.
The neurocircuitry of addiction: an overview.
Feltenstein M, See R
Br J Pharmacol. 2008; 154(2):261-74.
PMID: 18311189
PMC: 2442446.
DOI: 10.1038/bjp.2008.51.
Dopamine and incentive learning: a framework for considering antipsychotic medication effects.
Beninger R
Neurotox Res. 2007; 10(3-4):199-209.
PMID: 17197370
DOI: 10.1007/BF03033357.
Role of brain dopamine in food reward and reinforcement.
Wise R
Philos Trans R Soc Lond B Biol Sci. 2006; 361(1471):1149-58.
PMID: 16874930
PMC: 1642703.
DOI: 10.1098/rstb.2006.1854.
The economics of daily consumption controlling food- and water-reinforced responding.
Hursh S
J Exp Anal Behav. 1978; 29(3):475-91.
PMID: 16812071
PMC: 1332845.
DOI: 10.1901/jeab.1978.29-475.
Forebrain substrates of reward and motivation.
Wise R
J Comp Neurol. 2005; 493(1):115-21.
PMID: 16254990
PMC: 2562437.
DOI: 10.1002/cne.20689.
